

Lawrence A Leiter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2893346/publications.pdf>

Version: 2024-02-01

286
papers

47,498
citations

4120

87
h-index

1792

211
g-index

292
all docs

292
docs citations

292
times ranked

29995
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	13.9	4,159
2	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	13.9	3,898
3	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2013, 369, 1317-1326.	13.9	3,017
4	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2010, 362, 1563-1574.	13.9	2,460
5	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , The, 2019, 393, 31-39.	6.3	1,958
6	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
7	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2019, 394, 121-130.	6.3	1,625
8	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 1519-1529.	6.3	1,179
9	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080
10	Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
11	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1263-1282.	0.8	775
12	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2020, 382, 1507-1519.	13.9	758
13	Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. <i>New England Journal of Medicine</i> , 2017, 376, 1430-1440.	13.9	735
14	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
15	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	13.9	641
16	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	13.9	588
17	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	13.9	526
18	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523

#	ARTICLE	IF	CITATIONS
19	Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 502.	3.8	511
20	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 606-617.	5.5	482
21	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018, 34, 506-525.	0.8	474
22	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 382, 1520-1530.	13.9	463
23	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 941-950.	5.5	452
24	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 549-568.	0.8	431
25	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415
26	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016, 32, 569-588.	0.8	400
27	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 131-138.	6.3	394
28	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2019, 140, 1693-1702.	1.6	371
29	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	0.8	367
30	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
31	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	0.8	324
32	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1780.	3.8	314
33	Postprandial Glucose Regulation and Diabetic Complications. <i>Archives of Internal Medicine</i> , 2004, 164, 2090.	4.3	303
34	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	13.9	299
35	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2018, 277, 195-203.	0.4	298
36	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017, 33, 557-576.	0.8	269

#	ARTICLE	IF	CITATIONS
37	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
38	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 416-423.	1.3	255
39	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	13.9	255
40	Effect of Fructose on Body Weight in Controlled Feeding Trials. <i>Annals of Internal Medicine</i> , 2012, 156, 291.	2.0	253
41	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1227-1234.	1.6	241
42	The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. <i>Ophthalmology</i> , 2014, 121, 2443-2451.	2.5	239
43	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2020, 141, 704-707.	1.6	225
44	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224
45	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 485-501.	0.8	221
46	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018, 379, 1107-1117.	13.9	205
47	Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimperide in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. <i>Diabetes Care</i> , 2015, 38, 355-364.	4.3	197
48	Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 317-328.	5.5	195
49	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018, 138, 131-140.	1.6	194
50	Effect of Fructose on Glycemic Control in Diabetes. <i>Diabetes Care</i> , 2012, 35, 1611-1620.	4.3	191
51	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. <i>Diabetes Care</i> , 2014, 37, 2317-2325.	4.3	186
52	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
53	Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 32-37.	1.5	180
54	Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 831-9.	3.8	175

#	ARTICLE	IF	CITATIONS
55	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 889-897.	2.2	173
56	Design and baseline characteristics of participants in the <sc>R</sc>esearching cardiovascular <sc>E</sc>vents with a <sc>W</sc>eekly <sc>IN</sc>cretin in <sc>D</sc>iabetes (<sc>REWIND</sc>) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 42-49.	2.2	160
57	The Effects of Fructose Intake on Serum Uric Acid Vary among Controlled Dietary Trials. <i>Journal of Nutrition</i> , 2012, 142, 916-923.	1.3	158
58	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019, 394, 1169-1180.	6.3	155
59	Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 1213-1223.	2.2	150
60	Effect of fructose on postprandial triglycerides: A systematic review and meta-analysis of controlled feeding trials. <i>Atherosclerosis</i> , 2014, 232, 125-133.	0.4	146
61	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	1.0	142
62	Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 696-705.	4.3	141
63	Postprandial glucose regulation: New data and new implications. <i>Clinical Therapeutics</i> , 2005, 27, S42-S56.	1.1	140
64	Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24â€Week, Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Study with a 28â€Week Extension. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1252-1262.	1.3	137
65	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2017, 2, 370.	3.0	136
66	Sugar-sweetened beverage consumption and incident hypertension: a systematic review and meta-analysis of prospective cohorts. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 914-921.	2.2	134
67	Effect of Tree Nuts on Glycemic Control in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Dietary Trials. <i>PLoS ONE</i> , 2014, 9, e103376.	1.1	132
68	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
69	Metabolic Surgery. <i>Journal of the American College of Cardiology</i> , 2018, 71, 670-687.	1.2	130
70	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 1124.	3.0	128
71	Type 2 Diabetes Mellitus Management in Canada: Is It Improving?. <i>Canadian Journal of Diabetes</i> , 2013, 37, 82-89.	0.4	127
72	Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins. <i>Circulation</i> , 2018, 138, 1304-1316.	1.6	127

#	ARTICLE	IF	CITATIONS
73	Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition</i> , 2019, 38, 1133-1145.	2.3	123
74	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , The, 2020, 19, 582-590.	4.9	123
75	Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. <i>Diabetes Care</i> , 2015, 38, 1218-1227.	4.3	122
76	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1182-1193.	1.2	122
77	Konjac-Mannan and American Ginseng: Emerging Alternative Therapies for Type 2 Diabetes Mellitus. <i>Journal of the American College of Nutrition</i> , 2001, 20, 370S-380S.	1.1	121
78	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€“TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	1.2	117
79	Effect of tree nuts on metabolic syndrome criteria: a systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2014, 4, e004660-e004660.	0.8	112
80	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2016, 42, 25-32.	1.4	107
81	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DMâ€“INSULIN</scp> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1781-1792.	2.2	105
82	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 418-435.	5.5	105
83	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 172-183.	0.9	102
84	Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies. <i>BMJ: British Medical Journal</i> , 2018, 363, k4644.	2.4	102
85	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , 2020, 95, 77-89.	1.4	97
86	<scp>DECLAREâ€“TIMI</scp> 58: Participantsâ€™ baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	2.2	96
87	High-protein diets in hyperlipidemia: effect of wheat gluten on serum lipids, uric acid, and renal function. <i>American Journal of Clinical Nutrition</i> , 2001, 74, 57-63.	2.2	94
88	â€“Catalyticâ€™ doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. <i>British Journal of Nutrition</i> , 2012, 108, 418-423.	1.2	94
89	Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. <i>Journal of the American Heart Association</i> , 2015, 4, e001700.	1.6	94
90	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94

#	ARTICLE	IF	CITATIONS
91	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2210-2219.	2.2	87
92	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1â€“7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 880-893.	5.5	86
93	The prevention of diabetic microvascular complications of diabetes: Is there a role for lipid lowering?. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S3-S14.	1.1	85
94	American Ginseng Improves Glycemia in Individuals with Normal Glucose Tolerance: Effect of Dose and Time Escalation. <i>Journal of the American College of Nutrition</i> , 2000, 19, 738-744.	1.1	84
95	Effect of Replacing Animal Protein with Plant Protein on Glycemic Control in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2015, 7, 9804-9824.	1.7	81
96	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 173-176.	4.3	81
97	Day-to-Day Consistency in Amount and Source of Carbohydrate Intake Associated with Improved Blood Glucose Control in Type 1 Diabetes. <i>Journal of the American College of Nutrition</i> , 1999, 18, 242-247.	1.1	79
98	Persistent lipid abnormalities in statinâ€“treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. <i>Diabetic Medicine</i> , 2011, 28, 1343-1351.	1.2	79
99	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 106-114.	5.5	77
100	Alirocumab vs usual lipidâ€“lowering care as addâ€“on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€“DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	2.2	76
101	Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study. <i>Diabetes Care</i> , 2014, 37, 2723-2730.	4.3	75
102	Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2014, 37, 1806-1814.	4.3	75
103	Fructose intake and risk of gout and hyperuricemia: a systematic review and meta-analysis of prospective cohort studies. <i>BMJ Open</i> , 2016, 6, e013191.	0.8	74
104	Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 615-628.	2.2	73
105	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 1145-1153.	4.3	73
106	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€“TIMI 58 Study. <i>Diabetes Care</i> , 2020, 43, 468-475.	4.3	72
107	Association of Major Food Sources of Fructose-Containing Sugars With Incident Metabolic Syndrome. <i>JAMA Network Open</i> , 2020, 3, e209993.	2.8	72
108	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet</i> , 2018, 392, 2269-2279.	6.3	70

#	ARTICLE	IF	CITATIONS
109	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	0.6	70
110	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. <i>Cell Metabolism</i> , 2019, 30, 609-613.	7.2	69
111	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 73.	2.7	69
112	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	1.3	69
113	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	3.0	68
114	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
115	Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. <i>Diabetologia</i> , 2020, 63, 698-710.	2.9	58
116	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. <i>CMAJ Open</i> , 2017, 5, E152-E177.	1.1	57
117	Effects of blood pressure and lipid lowering on cognition. <i>Neurology</i> , 2019, 92, e1435-e1446.	1.5	54
118	Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2399-2414.	1.4	53
119	Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk. <i>JAMA Network Open</i> , 2022, 5, e222092.	2.8	52
120	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38.	1.2	51
121	Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. <i>Cardiovascular Research</i> , 2021, 117, 284-291.	1.8	51
122	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1164-1173.	2.3	51
123	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1805-1815.	4.3	49
124	Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. <i>Atherosclerosis</i> , 2007, 194, e154-e164.	0.4	48
125	Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary). <i>Canadian Journal of Cardiology</i> , 2011, 27, 124-131.	0.8	48
126	beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. <i>Diabetic Medicine</i> , 2005, 22, 963-972.	1.2	47

#	ARTICLE	IF	CITATIONS
127	Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub-analysis of ODYSSEY COMBO II. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 989-996.	2.2	46
128	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
129	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 438-444.	1.2	43
130	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 1-14.	1.1	43
131	Effect of Wheat Bran on Serum Lipids: Influence of Particle Size and Wheat Protein. <i>Journal of the American College of Nutrition</i> , 1999, 18, 159-165.	1.1	42
132	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. <i>Circulation</i> , 2015, 132, 2345-2350.	1.6	42
133	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 29.	2.7	42
134	Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance. <i>American Journal of Clinical Nutrition</i> , 2001, 73, 567-573.	2.2	40
135	Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals. <i>Canadian Journal of Diabetes</i> , 2014, 38, 38-44.	0.4	39
136	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , 2018, 190, E1192-E1206.	0.9	39
137	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 868-880.	2.2	38
138	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naïve patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 123-131.	5.5	37
139	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	0.8	37
140	The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2361-2370.	2.2	36
141	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose cotransporter 2 inhibitor therapy in DECLARE-TIMI 58. <i>European Journal of Heart Failure</i> , 2021, 23, 1026-1036.	2.9	35
142	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016, 129, 340.e1-340.e8.	0.6	34
143	The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 1132-1139.	1.1	33
144	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2058-2066.	2.2	33

#	ARTICLE	IF	CITATIONS
145	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019, 139, 366-375.	1.6	32
146	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
147	Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase <sc>III ODYSSEY</sc> clinical trials. <i>Diabetic Medicine</i> , 2018, 35, 121-130.	1.2	31
148	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-38.	2.2	31
149	The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2019, 42, 767-776.	4.3	31
150	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2487-2492.	2.2	31
151	CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection”and Maybe More. <i>Cell Metabolism</i> , 2017, 26, 703-705.	7.2	30
152	Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. <i>Stroke</i> , 2022, 53, 2749-2757.	1.0	30
153	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <sc>DECLARE-TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	2.2	28
154	From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 92.	2.7	28
155	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. <i>European Heart Journal</i> , 2022, 43, 2958-2967.	1.0	28
156	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. <i>Canadian Journal of Cardiology</i> , 2014, 30, 377-380.	0.8	27
157	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019, 18, 149.	2.7	27
158	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	2.2	26
159	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 801.	3.0	26
160	Frequency of cancer events with saxagliptin in the <sc>SAVOR-TIMI</sc> 53 trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 186-190.	2.2	25
161	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	2.7	25
162	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	0.8	25

#	ARTICLE	IF	CITATIONS
163	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018, 42, 130-137.	0.4	25
164	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.	1.6	25
165	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1159-1167.	4.3	25
166	Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 766-774.	2.2	24
167	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	0.8	24
168	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019, 42, 498-505.	0.7	24
169	Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN : ADD) <i>Tj ETQq1 1 0z784314 rgBT /Over</i>		
170	Impact of baseline glycosylated haemoglobin, diabetes duration and body mass index on clinical outcomes in the <i>LixiLan</i> trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (<i>GlarLixi</i>) vs insulin glargine and lixisenatide monocomponents. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1798-1804.	2.2	22
171	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 895-897.	0.4	22
172	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	2.7	22
173	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
174	The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, S167-S175.	0.4	20
175	The Effect of Small Doses of Fructose and Its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. <i>Nutrients</i> , 2018, 10, 1805.	1.7	20
176	Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 498-506.	1.3	20
177	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. <i>Pharmacoeconomics - Open</i> , 2019, 3, 537-550.	0.9	20
178	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, 938-946.	4.3	20
179	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	0.6	20
180	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. <i>Cmaj</i> , 2014, 186, 1299-1305.	0.9	19

#	ARTICLE	IF	CITATIONS
181	Effectiveness of gliclazide MR 60Âmg in the management of type 2 diabetes: analyses from the EASYDia trial. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 30.	1.2	19
182	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2389-2398.	2.2	19
183	The effect of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1690-1695.	2.2	19
184	The costâ€effectiveness of dapagliflozin in treating highâ€risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLAREâ€TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1020-1029.	2.2	19
185	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. <i>IScience</i> , 2021, 24, 103040.	1.9	19
186	Lifestyle modifications to prevent and control hypertension. 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. <i>Cmaj</i> , 1999, 160, S7-12.	0.9	19
187	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1594-1601.	2.2	18
188	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	1.0	18
189	Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?. <i>Clinical Biochemistry</i> , 2022, 99, 60-68.	0.8	18
190	Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 <scp>ODYSSEY</scp> trials. <i>Diabetic Medicine</i> , 2018, 35, 1742-1751.	1.2	17
191	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021, 42, 2565-2573.	1.0	17
192	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 484-490.	5.5	17
193	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. <i>Canadian Journal of Diabetes</i> , 2018, 42, 23-30.	0.4	16
194	Cardiovascular and renal benefits of dapagliflozin in patients with short and longâ€standing type 2 diabetes: Analysis from the DECLAREâ€TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1122-1131.	2.2	16
195	Time to cardiovascular benefits of empagliflozin: a <i>post hoc</i> observation from the EMPAâ€REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 2603-2607.	1.4	16
196	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 561-567.	1.3	16
197	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: Prognosis and implications for short- and long-term management. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 395-409.	0.9	15
198	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DMâ€INSULIN trial. <i>Diabetes and Metabolism</i> , 2017, 43, 453-459.	1.4	15

#	ARTICLE	IF	CITATIONS
199	Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1506-1512.	2.2	15
200	A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 1093-1100.	2.2	14
201	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. <i>Diabetes Therapy</i> , 2016, 7, 269-278.	1.2	14
202	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 277-284.	1.8	14
203	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020, 19, 199.	2.7	14
204	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , 2020, 7, 100039.	1.4	14
205	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1345-1351.	1.8	14
206	Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1288-1299.	2.2	14
207	Can thiazolidinediones delay disease progression in type 2 diabetes?. <i>Current Medical Research and Opinion</i> , 2006, 22, 1193-1201.	0.9	13
208	Use of GLP-1 RAs in Cardiovascular Disease Prevention. <i>Circulation</i> , 2018, 137, 2200-2202.	1.6	13
209	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2366-2377.	1.2	13
210	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	4.3	13
211	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
212	Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. <i>Nutrients</i> , 2022, 14, 2846.	1.7	13
213	Latest Evidence on Sulfonylureas: What's New?. <i>Diabetes Therapy</i> , 2020, 11, 15-22.	1.2	12
214	Different Food Sources of Fructose-Containing Sugars and Fasting Blood Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. <i>Journal of Nutrition</i> , 2021, 151, 2409-2421.	1.3	12
215	Gastrointestinal safety across the albiglutide development programme. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 930-935.	2.2	11
216	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. <i>Diabetes Research and Clinical Practice</i> , 2016, 112, 50-56.	1.1	11

#	ARTICLE	IF	CITATIONS
217	Effects of Changing the Amount and Source of Dietary Carbohydrates on Symptoms and Dietary Satisfaction Over a 1-Year Period in Subjects with Type 2 Diabetes: Canadian Trial of Carbohydrates in Diabetes (CCD). <i>Canadian Journal of Diabetes</i> , 2017, 41, 164-176.	0.4	11
218	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <i>Clinical Diabetes</i> , 2019, 37, 316-337.	1.2	11
219	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. <i>Canadian Journal of Diabetes</i> , 2019, 43, 384-391.	0.4	11
220	Use of bioelectrical impedance analysis measurements in patients with diabetes. The Diabetes Control and Complications Trial Research Group. <i>American Journal of Clinical Nutrition</i> , 1996, 64, 515S-518S.	2.2	10
221	Profile of adults with type 2 diabetes and uptake of clinical care best practices: Results from the 2011 Survey on Living with Chronic Diseases in Canada – Diabetes component. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 11-19.	1.1	10
222	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021, 52, 2494-2501.	1.0	10
223	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, e27-e29.	4.3	10
224	Optimal care of cardiovascular disease and type 2 diabetes patients: Shared responsibilities between the cardiologist and diabetologist. <i>Atherosclerosis Supplements</i> , 2006, 7, 37-42.	1.2	9
225	Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. <i>Clinical Obesity</i> , 2015, 5, 245-255.	1.1	9
226	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
227	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1378-1384.	1.2	9
228	Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1283-1285.	1.2	9
229	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674.	0.8	9
230	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. <i>Clinical Chemistry</i> , 2019, 65, 781-790.	1.5	8
231	Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial. <i>European Journal of Nutrition</i> , 2021, 60, 3071-3083.	1.8	8
232	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. <i>Diabetes Care</i> , 2021, 44, 8-10.	4.3	8
233	Effects of L-Tryptophan on Food Intake and Selection in Lean Men and Women. <i>Annals of the New York Academy of Sciences</i> , 2006, 499, 327-328.	1.8	7
234	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. <i>BMJ Open</i> , 2016, 6, e012220.	0.8	6

#	ARTICLE	IF	CITATIONS
235	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
236	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017, 33, 940-942.	0.8	5
237	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020, 221, 60-66.	1.2	5
238	A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study. <i>JMIR Human Factors</i> , 2022, 9, e34704.	1.0	5
239	Diabetic dyslipidaemia: Effective management reduces cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2005, 6, 37-43.	1.2	4
240	Attainment of Canadian and European guidelines™ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. <i>International Journal of Clinical Practice</i> , 2010, 64, 1765-1772.	0.8	4
241	Obesity“It Must Not Remain the Neglected Risk Factor in Cardiology. <i>Canadian Journal of Cardiology</i> , 2015, 31, 105-108.	0.8	4
242	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1350-1361.	0.8	4
243	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , 2020, 2, 49-54.	0.7	4
244	Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 332-336.	2.2	4
245	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 704-712.	2.2	4
246	From hyperglycemia to the risk of cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7 Suppl 2, S3-9.	0.5	4
247	Cost“effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 777-785.	1.4	4
248	Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1998-2007.	2.2	4
249	Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial. <i>BMJ Open</i> , 2017, 7, e015026.	0.8	3
250	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment “ a clinical appraisal. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1451-1457.	1.2	3
251	4945Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial. <i>European Heart Journal</i> , 2019, 40, .	1.0	3
252	Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed“ratio combination: a post hoc analysis of the LixiLan“ and LixiLan“L trials. <i>Diabetic Medicine</i> , 2020, 37, 256-266.	1.2	3

#	ARTICLE	IF	CITATIONS
253	Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 2.	1.3	3
254	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , 2021, 75, e13861.	0.8	3
255	1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial. <i>Diabetes</i> , 2020, 69, .	0.3	3
256	Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6. <i>European Heart Journal</i> , 2021, 42, .	1.0	3
257	How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. <i>Journal of Family Practice</i> , 2008, 57, 661-8.	0.2	3
258	Dosing Irregularities and Self-Treated Hypoglycemia in Type 2 Diabetes: Results from the Canadian Cohort of an International Survey of Patients and Healthcare Professionals. <i>Canadian Journal of Diabetes</i> , 2015, 39, 19-25.	0.4	2
259	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
260	A LEADER in the management of type 2 diabetes and cardiorenal disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 978-984.	0.4	2
261	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 143-153.	0.5	2
262	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107997.	1.2	2
263	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, , CIRCINTERVENTIONS120011035.	1.4	2
264	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3448-e3454.	1.8	2
265	PROVE-IT proved it: Lower is better â€œ Pro. <i>Canadian Journal of Cardiology</i> , 2006, 22, 91B-94B.	0.8	1
266	Questioning the safety and benefits of evolocumab â€œ Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 11-12.	5.5	1
267	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	1
268	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. <i>Diabetes and Metabolism</i> , 2020, 46, 280-287.	1.4	1
269	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. <i>Canadian Journal of Diabetes</i> , 2021, , .	0.4	1
270	Tree nuts improve criteria of the metabolic syndrome: a systematic review and meta-analysis of randomized controlled dietary trials (1025.6). <i>FASEB Journal</i> , 2014, 28, 1025.6.	0.2	1

#	ARTICLE	IF	CITATIONS
271	The use of bioelectrical impedance analysis (BIA) to estimate body composition in the Diabetes Control and Complications Trial (DCCT)., 1994, 18, 829-35.		1
272	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI. American Heart Journal, 2022, 249, 23-23.	1.2	1
273	Diagnosis of coronary artery disease in the diabetic patient. Canadian Journal of Cardiology, 2006, 22, 7A-8A.	0.8	0
274	Correctly understanding the diabetes data in FOURIER. Diabetes, Obesity and Metabolism, 2019, 21, 2342-2343.	2.2	0
275	4113Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials. European Heart Journal, 2019, 40, .	1.0	0
276	P5364Safety profile of bempedoic acid: pooled analysis of 4 phase 3 clinical trials. European Heart Journal, 2019, 40, .	1.0	0
277	Long Term Effectiveness of A Dietary Portfolio of Cholesterolá€Lowering Foods in Hypercholesterolemic Subjects. FASEB Journal, 2008, 22, 460.8.	0.2	0
278	Effect of tree nuts on glycemic control in diabetes: a systematic review and metaá€analysis of randomized controlled dietary trials (1025.16). FASEB Journal, 2014, 28, 1025.16.	0.2	0
279	Tree Nuts Improve Glycemic Control: A Systematic Review and Metaá€Analysis of Randomized Controlled Dietary Trials. FASEB Journal, 2015, 29, 383.1.	0.2	0
280	Effect of a Low Glycemic Index Diet on Markers of Oxidative Damage in Type 2 Diabetes. FASEB Journal, 2015, 29, 274.5.	0.2	0
281	Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials. European Heart Journal, 2021, 42, .	1.0	0
282	Response to the Letter on á€œThe Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitusá€• Cardiovascular Drugs and Therapy, 2022, , 1.	1.3	0
283	Estrogens are indicated for the prevention of coronary artery disease: a debate for estrogen. Canadian Journal of Cardiology, 2000, 16 Suppl E, 13E-16E.	0.8	0
284	Case 1. Cardiovascular dysfunction syndrome. Canadian Journal of Cardiology, 2000, 16 Suppl E, 21E-23E.	0.8	0
285	459á€fEvaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither. European Heart Journal Supplements, 2021, 23, .	0.0	0
286	Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines tÃglichen vs. wÃrchentlichen Titrationsalgorithmus fÃ¼r den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0